Compounders Research Compare

Oncolytics Biotech Inc.(ONCY)

Biotechnology · San Diego, CA

$0.60+0.00 (+0.50%)

Delayed quote: Oct 6, 2026, 3:15 PM EDT

About Oncolytics Biotech Inc.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

San Diego, CA

29 employees

www.oncolyticsbiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jared Kelly

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T19:17:57.291Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:17:57.291Z.

Quote observation: 2026-10-06T19:15:22.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 60,206,565
Total debt · period ending 2026-06-30: 448,000
Cash · period ending 2026-06-30: 4,115,000
TTM free cash flow · period ending 2026-06-30: -23,124,752.245999996

FMP input reference: d71c6897c98d436948f76d79272a6a7ae3c560285f8867db41996dc6a6301e16

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ONCY EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ONCY Competitors' EV/FCF Ratio

Oncolytics Biotech Inc.

Current

Market Cap

$60.21M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kalaris Therapeutics Inc

Market Cap

$60.46M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Xilio Therapeutics, Inc.

Market Cap

$60.49M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDS Biotechnology Corporation

Market Cap

$60.68M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Fractyl Health, Inc.

Market Cap

$60.95M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Adicet Bio, Inc.

Market Cap

$59.01M

EV/FCF Ratio

N/A

TTM Avg

108.20x

3Y Avg

108.20x

5Y Avg

108.20x

Connect Biopharma Holdings Limited

Market Cap

$58.75M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MiNK Therapeutics, Inc.

Market Cap

$58.54M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Heron Therapeutics, Inc.

Market Cap

$61.95M

EV/FCF Ratio

N/A

TTM Avg

1.41x

3Y Avg

1.41x

5Y Avg

1.41x

Boundless Bio, Inc.

Market Cap

$58.21M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Oncolytics Biotech Inc. (ONCY)	$60.21M	N/A	N/A	N/A	N/A
Kalaris Therapeutics Inc (KLRS)vs ›	$60.46M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$60.49M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$60.68M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$60.95M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$59.01M	N/A	108.20x	108.20x	108.20x
Connect Biopharma Holdings Limited (CNTB)vs ›	$58.75M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$58.54M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$61.95M	N/A	1.41x	1.41x	1.41x
Boundless Bio, Inc. (BOLD)vs ›	$58.21M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics